NCT00095654View on ClinicalTrials.gov

The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

5,000

Participants

Timeline

Start Date

July 31, 2001

Study Completion Date

October 31, 2006

Conditions
Impaired Glucose ToleranceCardiovascular DiseaseGlucose Metabolism Disorders
Interventions
DRUG

Ramipril

DRUG

Rosiglitazone

Sponsors
All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Aventis Pharmaceuticals

INDUSTRY

collaborator

GlaxoSmithKline

INDUSTRY

collaborator

King Pharmaceuticals is now a wholly owned subsidiary of Pfizer

INDUSTRY

collaborator

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

Gerstein, Hertzel, MD

INDIV